Premium
Serum levels of tissue factor pathway inhibitor: Potential association with Raynaud’s phenomenon and telangiectasia in patients with systemic sclerosis
Author(s) -
Norimatsu Yuta,
Miyagawa Takuya,
Fukui Yuki,
Omatsu Jun,
Toyama Satoshi,
Awaji Kentaro,
Ikawa Tetsuya,
Watanabe Yusuke,
Yoshizaki Ayumi,
Sato Shinichi,
Asano Yoshihide
Publication year - 2021
Publication title -
the journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.9
H-Index - 65
eISSN - 1346-8138
pISSN - 0385-2407
DOI - 10.1111/1346-8138.15893
Subject(s) - medicine , tissue factor pathway inhibitor , telangiectasia , coagulation , fibrosis , inflammation , tissue factor , scleroderma (fungus) , systemic scleroderma , immunology , pathology , disease , inoculation
Vasculopathy is a critical step of systemic sclerosis (SSc) development, bridging between autoimmune inflammation and tissue fibrosis. Impaired coagulation system is a part of SSc vasculopathy, but the role of tissue factor pathway inhibitor (TFPI), a critical regulator of the extrinsic coagulation pathway, remained unknown. Therefore, we evaluated the clinical correlation of serum TFPI levels in SSc patients. Serum TFPI levels were comparable between SSc and control participants, but SSc patients with Raynaud’s phenomenon and telangiectasia had significantly lower serum TFPI levels than those without. Importantly, there was a significant positive correlation between serum TFPI levels and protein S activity. These results support the critical role of impaired coagulation system in SSc.